Umberto Malapelle
Federico II University Hospital · 640 works · 11,246 citations · h-index 57
Top works
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
- The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
- Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)
- Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
- Cytology in the time of coronavirus disease (COVID-19): an Italian perspective
- Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients
- Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
- EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
- CBX7 is a tumor suppressor in mice and humans
- EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study
- EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patients
- Cytology‐based gene mutation tests to predict response to anti‐epidermal growth factor receptor therapy: A review
- Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients
- Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
- Cytopathologists can reliably perform ultrasound‐guided thyroid fine needle aspiration: a 1‐year audit on 3715 consecutive cases
- Immunotherapy in non-small cell lung cancer harbouring driver mutations
- How to prepare cytological samples for molecular testing
- The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
- Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
- Challenges and opportunities of next‐generation sequencing: a cytopathologist's perspective